What is the low-grade fever temperature in leukemia?

Sep 22, 2025 Source: Cainiu Health

Dr. Liu Feng

Introduction

In general, low-grade fever in leukemia patients usually ranges between 37.3°C and 38°C, and this mild fever may persist or recur intermittently; therefore, it should be monitored comprehensively along with other clinical features and symptoms. In daily life, patients should be provided with a comfortable and well-ventilated resting environment, ensuring adequate sleep and nutritional intake to enhance their physical tolerance.

Under normal circumstances, low-grade fever in leukemia patients typically ranges between 37.3°C and 38°C. This low-grade fever may persist or recur repeatedly and should be comprehensively monitored in conjunction with the disease characteristics and other clinical manifestations. Specific analysis is as follows:

The low-grade fever observed in leukemia patients usually does not exceed 38°C, with 37.3°C–38°C being the typical range. This type of fever often occurs without obvious triggers—such as exposure to cold or infection—and may show limited response to common antipyretic medications; even if body temperature temporarily decreases, it tends to rise again quickly. Some patients may also experience accompanying symptoms such as fatigue, pallor, and skin bruising alongside the low-grade fever, all of which warrant close attention. In daily care, physical methods such as tepid sponge baths can help regulate body temperature. Avoid using potent antipyretics indiscriminately to prevent masking underlying disease progression.

In daily life, it's important to provide patients with a comfortable and well-ventilated resting environment, ensure adequate sleep and nutritional intake, and enhance their physical resilience. Regular monitoring of body temperature is also essential to allow timely adjustments to treatment and nursing plans based on disease progression.

View All

Can early-stage leukemia in children be cured?

In general, whether early-stage leukemia in children can be cured depends on the type of leukemia. Early-stage acute lymphoblastic leukemia is mostly curable, while some types of acute myeloid leukemia can be cured at the initial stage. Chronic myeloid leukemia is more difficult to cure completely in the early stage, but its progression can be controlled through treatment. In daily care, it is important to ensure balanced nutrition for the child, including adequate intake of protein and vitamins.

View Full Answer

Can acute myeloid leukemia M2A be cured?

In general, whether acute myeloid leukemia M2A can be cured depends on the severity of the disease. Patients with low- or intermediate-risk M2A have a good chance of cure with standardized treatment, while those with high-risk M2A are more difficult to cure, although active treatment can prolong survival. In daily care, it is important to provide patients with a clean and hygienic environment to prevent infections.

View Full Answer

Is the blood of leukemia patients contagious?

Under normal circumstances, the blood of leukemia patients is not contagious. Leukemia is not an infectious disease; its development is associated with factors such as genetics, environment, and immune system abnormalities, and there is no possibility of transmission to others through blood contact. Therefore, there is no need to worry about contracting the disease through contact with the blood of leukemia patients. Patients should receive normal social interaction and care, and concerns about contagion should be eliminated.

View Full Answer

Is acute myeloid leukemia M5 type severe?

In general, acute monocytic leukemia (M5) is one of the subtypes of acute myeloid leukemia with relatively high malignancy and carries a serious overall prognosis. However, outcomes vary among individuals and are influenced by factors such as patient age, chromosomal abnormalities, and timing of treatment. After diagnosis, individualized therapy should be initiated promptly in a hematology specialty setting. Younger patients who meet the criteria should actively pursue hematopoietic stem cell transplantation.